Drug Profile
Rasagiline - Teva Pharmaceutical Industries
Alternative Names: Agilect; AGN 1135; Azilect; Elbrus; Lu 00-773; Rasagiline mesilate; Rasagiline mesylate; TV-1030; TVP 101; TVP 1012Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Technion - Israel Institute of Technology
- Developer Lundbeck A/S; Takeda; Teva Pharmaceutical Industries
- Class Amines; Antiparkinsonians; Indans; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
- Discontinued Alzheimer's disease
Most Recent Events
- 01 Nov 2018 Takeda plans a post-marketing surveillance study for Parkinson's disease in Japan (JapicCTI-184181)
- 30 Oct 2018 Launched for Parkinson's disease in Japan (PO) (JapicCTI-184181))
- 01 Mar 2018 Registered for Parkinson's disease in Japan (PO) (Takeda pipeline, May 2018)